Evidence map›Paper›PMID 33912162›Full record

ReviewFrontiers in immunology2021

The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.

Prerna Malaney, María Velasco-Estevez, Pedro Aguilar-Garrido, Marisa J L Aitken, Lauren E Chan, Xiaorui Zhang, Sean M Post, Miguel Gallardo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. The Role of RNA-Binding Proteins in Hematological Malignancies.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Prerna MalaneyDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, United States.
María Velasco-EstevezH12O-CNIO Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain.
Pedro Aguilar-GarridoH12O-CNIO Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain.
Marisa J L AitkenDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, United States.
Lauren E ChanDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, United States.
Xiaorui ZhangDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, United States.
Sean M PostDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, United States.
Miguel GallardoH12O-CNIO Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain.
The University of Texas MD Anderson Cancer Center · USSpanish National Cancer Research Centre · ES

Funding

Personalized therapy for AML patients with a newly identified genetic alterationR01CA207204 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI POST, SEAN M · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA207204
6 · The paper itself

Abstract

B-cell lymphomas are one of the most biologically and molecularly heterogeneous group of malignancies. The inherent complexity of this cancer subtype necessitates the development of appropriate animal model systems to characterize the disease with the ultimate objective of identifying effective therapies. In this article, we discuss a new driver of B-cell lymphomas - hnRNP K (heterogenous nuclear ribonucleoprotein K)-an RNA-binding protein. We introduce the

Indexed as

AnimalsAnimals, Genetically ModifiedB-LymphocytesCell Transformation, NeoplasticDisease Models, AnimalGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHeterogeneous-Nuclear Ribonucleoprotein KLymphoma, B-CellPhenotypeProto-Oncogene Proteins c-mycUp-RegulationHeterogeneous-Nuclear Ribonucleoprotein KMYC protein, humanProto-Oncogene Proteins c-mycB-cell malignanciesdiffuse large B cell lymphomaEµ-HnrnpkhnRNP Klymphomamouse modelMYCRNA-binding protein

Identifiers

PMID33912162
PMCPMC8072109
OpenAlexW3156456196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.